A Phase 3 interventional study of olaparib and enzalutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Completed at 204 sites in 20 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.
Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 3, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zin W Myint · Sites in United States
Ages 18+ · Men only
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 130 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 387 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 25 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 17th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2017, is one of 17 in phase 3, and was the 45th registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
2 of the studies testing olaparib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04038502VA Office of Research and DevelopmentCarboplatin or Olaparib for BRcA Deficient Prostate Cancer | 2027-08-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing olaparib in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
This is a prospective, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of olaparib versus enzalutamide or abiraterone in subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have a qualifying tumor mutation in one of 15 genes involved in the homologous recombination repair (HRR) pathway. Subjects will be divided into two cohorts based on HRR gene mutation status.
Approximately 340 subjects will be randomized 2:1 (olaparib : investigator choice of enzalutamide or abiraterone acetate) into the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
Drug: olaparib
Enzalutamide: Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily. Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary.
Drug: enzalutamide · Drug: abiraterone acetate
300 mg (2x 150 mg tablets) twice daily
Also known as: Lynparza
160 mg (4 x 40 mg capsules) once daily
Also known as: XTANDI
1,000 mg (4 x 250 mg tablets) once daily
Also known as: ZYTIGA
1,000 mg (2 x 500 mg tablets) once daily
Also known as: ZYTIGA
160 mg (4 x 40 mg tablets) once daily
Also known as: XTANDI
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only
The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \>=20% increase in the sum of diameters of target lesions and an absolute increase of \>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \>=6 weeks later, must show \>=2 more new bone lesions (for a total of \>=4 new bone lesions since baseline).
Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only
ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.
Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B
The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.
Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Time to Pain Progression - Cohort A Only
Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \[Item 3\] and Analgesic Quantification Algorithm \[AQA\] score.
Time frame: Every 4 weeks from randomisation (for 7 consecutive days) throughout the study (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Overall Survival (OS) - Cohort A Only
Number of Participants with Overall Survival (OS) - Cohort A only.
Time frame: Approximately 35 months after the first patient was randomised.
Subjects were divided into two cohorts based on HRR gene mutation status. Subjects with mutations in either BRCA1, BRCA2, or ATM are in Cohort A whereas subjects with mutations among 12 other genes involved in the HRR pathway (BARD1, BRIP1, CDK12, CHEK1,CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L) are in Cohort B.
| Milestone | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA | Cohort B Olaparib 300mg bd | Cohort B Investigators Choice of NHA |
|---|---|---|---|---|
| Started | 162 | 83 | 94 | 48 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 162 | 83 | 94 | 48 |
| Withdrew: Ongoing study at data cut off | 49 | 21 | 19 | 12 |
| Withdrew: Death | 88 | 54 | 67 | 28 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 21 | 7 | 7 | 6 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 |
ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.
| Participants | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA |
|---|---|---|
| Response | 28 | 1 |
| No response | 56 | 42 |
The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.
| Months | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA |
|---|---|---|
| Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B | 5.82 (5.52 to 7.36) | 3.52 (2.2 to 3.65) |
Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \[Item 3\] and Analgesic Quantification Algorithm \[AQA\] score.
| Months | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA |
|---|---|---|
| Time to Pain Progression - Cohort A Only | NA (NA to NA) | 9.92 (5.39 to NA) |
Number of Participants with Overall Survival (OS) - Cohort A only.
| Participants | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA |
|---|---|---|
| Died | 91 | 57 |
| Alive at data cut-off | 49 | 21 |
| Terminated prior to death (withdrawn consent) | 22 | 5 |
The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \>=20% increase in the sum of diameters of target lesions and an absolute increase of \>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \>=6 weeks later, must show \>=2 more new bone lesions (for a total of \>=4 new bone lesions since baseline).
| Months | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA |
|---|---|---|
| Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only | 7.39 (6.24 to 9.33) | 3.55 (1.91 to 3.71) |
Collected over From the time of signature of informed consent throughout the treatment period (median duration of treatment of 7.5 and 3.9 months for Olaparib and Investigators Choice of NHA respectively) up to and including the 30-day follow-up period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A+B Olaparib 300mg bd | 160/256 (62.5%) | 94/256 (36.7%) | 241/256 (94.1%) |
| Cohort A+B Investigators Choice of NHA | 88/131 (67.2%) | 39/130 (30%) | 112/130 (86.2%) |
| Event | Cohort A+B Olaparib 300mg bd | Cohort A+B Investigators Choice of NHA |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 23/256 | 0/130 |
| PneumoniaInfections and infestations | 11/256 | 4/130 |
| Urinary tract infectionInfections and infestations | 5/256 | 4/130 |
| SepsisInfections and infestations | 3/256 | 3/130 |
| DehydrationMetabolism and nutrition disorders | 0/256 | 3/130 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/256 | 1/130 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/256 | 0/130 |
| VomitingGastrointestinal disorders | 4/256 | 1/130 |
| AstheniaGeneral disorders | 4/256 | 1/130 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/256 | 1/130 |
| Event | Cohort A+B Olaparib 300mg bd | Cohort A+B Investigators Choice of NHA |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 110/256 | 20/130 |
| NauseaGastrointestinal disorders | 109/256 | 26/130 |
| Decreased appetiteMetabolism and nutrition disorders | 78/256 | 24/130 |
| FatigueGeneral disorders | 68/256 | 28/130 |
| DiarrhoeaGastrointestinal disorders | 54/256 | 9/130 |
| ConstipationGastrointestinal disorders | 49/256 | 19/130 |
| VomitingGastrointestinal disorders | 49/256 | 17/130 |
| AstheniaGeneral disorders | 37/256 | 18/130 |
| Back painMusculoskeletal and connective tissue disorders | 36/256 | 17/130 |
| Oedema peripheralGeneral disorders | 34/256 | 10/130 |
| Age, Continuous(Years) | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA | Cohort B Olaparib 300mg bd | Cohort B Investigators Choice of NHA | Total |
|---|---|---|---|---|---|
| Mean | 68.0 ± 8.23 | 68.1 ± 7.36 | 69.2 ± 8.79 | 70.3 ± 7.83 | 68.6 ± 8.15 |
| Sex: Female, Male(Participants) | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA | Cohort B Olaparib 300mg bd | Cohort B Investigators Choice of NHA | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 162 | 83 | 94 | 48 | 387 |
| Race/Ethnicity, Customized(Participants) | Cohort A Olaparib 300mg bd | Cohort A Investigators Choice of NHA | Cohort B Olaparib 300mg bd | Cohort B Investigators Choice of NHA | Total |
|---|---|---|---|---|---|
| White | 109 | 55 | 54 | 30 | 248 |
| Black or African American | 2 | 1 | 5 | 0 | 8 |
| Asian | 43 | 19 | 26 | 17 | 105 |
| Other | 1 | 1 | 1 | 0 | 3 |
| Missing | 7 | 7 | 8 | 1 | 23 |
Showing the first 100 of 204 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jun 2019, 27 months.
Results were first posted in Oct 2020, 1 year 4 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 27 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib